How Does TMS Work?

What TMS Actually Does in the Brain

The immediate physiological effect depends on where the coil is positioned, how strong the stimulation is, how frequently pulses are delivered, how many pulses are given, and the temporal pattern used. These variables are why the term “TMS” describes a family of stimulation protocols rather than one identical treatment. A clinician selects a protocol based on the treatment indication, device capabilities, patient-specific considerations, and the evidence supporting that protocol.

The U.S. Food and Drug Administration describes repetitive TMS systems for major depressive disorder as electromagnetic devices that noninvasively deliver rapidly pulsed magnetic fields to the cerebral cortex to activate neurons within a limited volume without intentionally inducing a seizure. That distinction is important: TMS is designed to influence targeted cortical activity while a patient is awake, rather than producing the generalized seizure used therapeutically in electroconvulsive therapy.

Why the Target Matters

The brain works through distributed networks. A cortical site is not useful simply because it lies under a convenient scalp location; it matters because that cortical region participates in a network relevant to the symptom or disorder being treated. For major depressive disorder, many clinical TMS protocols target the left dorsolateral prefrontal cortex, a frontal region that interacts with limbic and cognitive-control systems involved in mood regulation. Other indications use different targets because the relevant circuits are different.

Target selection can be performed in several ways. Some clinical systems use standardized scalp measurements, motor-cortex-based rules, or device-specific positioning methods. Other approaches incorporate structural imaging, functional imaging, or EEG-derived information. These approaches should not be treated as interchangeable claims of superiority. The appropriate method depends on the clinical protocol being used, the available device, and the treatment question.

At Neurolimits, the important practical principle is that stimulation should be intentional: the team should be able to explain which target is being stimulated, why that target was selected, what protocol is being delivered, and how progress will be measured. The main TMS in Austin service page explains how this is incorporated into treatment at Neurolimits.

Frequency, Pattern, Intensity, and Dose

TMS effects are shaped by stimulation parameters. Conventional repetitive TMS may deliver pulses at a fixed frequency such as 1 Hz or 10 Hz. Theta-burst stimulation delivers short bursts of high-frequency pulses repeated at a theta-frequency rhythm. Different patterns can influence cortical excitability differently, and different FDA-cleared systems use protocol-specific dosing rules.

Intensity is commonly referenced to an individual motor threshold. Motor threshold is an experimentally determined measure of how much stimulator output is needed to produce a reliable motor response when stimulating motor cortex. It provides a patient-specific physiological reference rather than assuming that every person should receive the same percentage of machine output.

Treatment dose is more than intensity alone. Clinicians also consider pulses per session, sessions per week, total number of sessions, target, coil type, and protocol. This is one reason a statement such as “I tried TMS once” can be misleading; a full therapeutic course is a repeated intervention delivered over time, not a single pulse or isolated session.

Why TMS Is Repeated Over Multiple Sessions

A single TMS session can transiently alter cortical excitability, but clinical treatment is typically delivered repeatedly because the therapeutic objective is a more durable change in network function. Repeated stimulation can engage plasticity-related mechanisms, meaning the nervous system changes its response as stimulation is delivered across a course.

In clinical practice, symptom improvement is therefore assessed longitudinally. A patient may notice change gradually rather than during the stimulation itself. The clinic should track symptoms using standardized scales and clinical follow-up instead of interpreting sensations during a session as evidence that treatment is or is not working.

The number and timing of sessions depend on the indication and protocol. Patients should receive a clear treatment plan at the beginning of care, including what constitutes the acute course, how progress will be assessed, and what options exist if improvement is incomplete.

What a TMS Session Feels Like

During a typical session, the patient sits in a treatment chair while the coil is positioned against the scalp. The device produces audible clicks and a tapping or knocking sensation at the stimulation site. The patient remains awake and can communicate with the treatment team throughout the session. Hearing protection is generally used because of the sound produced by the coil.

Scalp discomfort or headache can occur, particularly early in a course, and clinicians may adjust positioning or titrate intensity when appropriate. A treatment team should also review medications, seizure history, implanted devices or metal, neurological history, and other safety considerations before treatment. TMS has a known but low seizure risk, which is one reason screening and protocol adherence matter.

Because TMS does not require anesthesia for standard outpatient psychiatric treatment, patients generally leave the clinic after the session. Individual instructions should still come from the treating clinician, especially when a patient has other medical or neurological considerations.

TMS vs. ECT vs. Neurofeedback

TMS and electroconvulsive therapy are both brain-based treatments, but they are not the same procedure. Standard clinical TMS uses focal magnetic stimulation while the patient is awake and does not intentionally induce a seizure. ECT is performed under anesthesia and intentionally induces a controlled generalized seizure. ECT remains an important treatment in psychiatry, particularly for severe or urgent illness, but its procedure, indications, logistics, and risk profile differ substantially from outpatient TMS.

TMS also differs from neurofeedback. TMS actively stimulates cortical tissue with magnetic pulses. Neurofeedback records brain activity, typically with EEG, and returns information to the participant in real time so that patterns of activity can be trained through feedback and reinforcement. EEG itself is a recording method; it does not stimulate the brain.

These distinctions matter because people searching for “brain stimulation” or “brain training” may encounter very different interventions. Neurolimits offers multiple neuroscience-based services, but each has a different mechanism and should be selected for a specific clinical or performance goal.

FDA Status and Evidence for Depression

The FDA first cleared a repetitive TMS system for treatment of major depressive disorder in adults in 2008. That clearance was based on a defined device, protocol, indication, and patient population; it should not be interpreted to mean that every possible TMS protocol is FDA-cleared for every psychiatric or neurological condition.

A pivotal randomized, sham-controlled multicenter trial by O'Reardon and colleagues evaluated left-prefrontal TMS in adults with major depression who had not benefited sufficiently from prior antidepressant treatment. The trial contributed to the evidence base supporting clinical use of TMS for depression. Since then, multiple devices and protocol variations have received FDA clearances for specific indications.

Neurolimits should describe a treatment as FDA-cleared only when the specific device/protocol/indication being used meets that regulatory status. Other uses may be offered off label when clinically appropriate, but the distinction should be stated clearly rather than implying universal FDA approval. Learn more about TMS for OCD, which uses a different FDA clearance and treatment framework.

How Neurolimits Uses This Information

At Neurolimits, TMS treatment planning begins with clinical screening rather than with a generic protocol menu. The treatment team reviews the diagnosis being treated, symptom severity, prior treatments, medications, relevant medical and neurological history, contraindications, and the patient's goals. The stimulation target and protocol are then selected within the clinical framework appropriate to that indication.

Progress should be tracked across the course using standardized symptom measures and clinical follow-up. If symptoms are not improving as expected, the response should be reviewed rather than simply continuing the same plan without reassessment.

For people specifically looking for TMS in Austin, the next step is the main Neurolimits TMS service page, which explains candidacy, conditions treated, the clinic process, and how to schedule a consultation. For depression specifically, see TMS for depression in Austin.